We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Creo Medical Group Plc | LSE:CREO | London | Ordinary Share | GB00BZ1BLL44 | ORD GBP0.001 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 36.25 | 36.00 | 36.50 | 36.25 | 36.25 | 36.25 | 299,147 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Surgical,med Instr,apparatus | 27.17M | -26.94M | -0.0746 | -4.86 | 130.95M |
From Apr 2019 to Apr 2024
TIDMCREO
RNS Number : 4588Y
Creo Medical Group PLC
21 August 2018
21 August 2018
Creo Medical Group plc
("Creo" or the "Company")
Placing - Expected timetable to completion
Creo Medical Group plc (AIM: CREO) is pleased to announce that, further to the announcements made on 13 July and 1 August 2018, Additional VCT Advanced Assurance from HMRC has been received. Application has been made for admission to AIM of the Additional EIS/VCT Shares and the Non EIS/VCT Shares ("Admission") and the Company expects that Admission will become effective at 8.00 a.m. on Thursday 30 August 2018 and following such Admission that all conditions relating to the Placing will have been satisfied.
Following Admission of the Additional EIS/VCT Shares and the Non EIS/VCT Shares, the Company's issued ordinary share capital will consist of 119,923,065 Ordinary Shares; no shares are held in treasury. The above figure of 119,923,065 Ordinary Shares may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the voting rights of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Further details regarding the Placing and the Placing Shares can be found in the announcement issued by the Company on 13 July 2018 and in the Circular posted to Shareholders on that same day, which are available to view on the Company's website: investors.creomedical.com. Capitalised terms used, but not defined, in this announcement shall have the same meaning as set out in the Circular.
Contacts:
Creo Medical: +44 (0)129 160 6005 Richard Rees Cenkos: +44 (0)207 397 8900 Mark Connelly (NOMAD) Michael Johnson / Russell Kerr (Sales) FTI Consulting: +44 (0)203 727 1000 Brett Pollard / Mo Noonan creo@fticonsulting.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
ALSUASURWOAWUAR
(END) Dow Jones Newswires
August 21, 2018 08:48 ET (12:48 GMT)
1 Year Creo Medical Chart |
1 Month Creo Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
